Metsera-Pfizer-Novo updates; Why the FDA drug chief resigned; The “big flaw” in Big Pharma’s patient advocacy.

Pfizer Inc said on Monday it has filed a second lawsuit against drug developer Metsera , its controlling shareholder, and Novo Nordisk in a Delaware federal court, accusing the Danish drugmaker of ...

Pfizer insists that Novo Nordisk’s unsolicited offer to acquire Metsera is an effort from the Danish pharma to “suppress ...

Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political ...

Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless” ...

Novo Nordisk made a much higher offer to acquire a biotech Pfizer was already set to buy out. Losing this battle would be more damaging to Pfizer than to Novo Nordisk. Even so, both companies look ...

Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted developer of obesity drugs.

Lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing off a smaller competitor.

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting ...